Skip to content
Peptidepedia

How to Use GHRP-6: Administration, Reconstitution & Storage (2026)

From Peptidepedia, the trusted peptide wiki.

How to Use / Administration Methods

GHRP-6 is administered via subcutaneous injection, typically into abdominal fat, the thigh, or the deltoid region.

Timing is critical. GHRP-6 should be injected on an empty stomach, at least 30 minutes before eating or 2 or more hours after a meal. Elevated blood glucose and insulin significantly blunt the GH response. Given GHRP-6's intense appetite stimulation, most users eat their meal 20 to 30 minutes post-injection, effectively using the peptide as a pre-meal trigger.

Injection process:

  1. Reconstitute the lyophilized powder with bacteriostatic water (see Reconstitution section below)
  2. Draw the appropriate dose into an insulin syringe (29 to 31 gauge)
  3. Pinch a fold of skin at the injection site
  4. Insert the needle at a 45 to 90 degree angle
  5. Slowly depress the plunger
  6. Hold for 5 seconds before withdrawing; dispose of the needle properly

Injection sites should be rotated to prevent lipodystrophy. The pre-bed injection is widely considered the most important administration window, as it amplifies the body's largest natural GH pulse during deep sleep.

Reconstitution, Storage & Prep

GHRP-6 is supplied as a lyophilized (freeze-dried) powder that requires reconstitution before use.

Reconstitution Process:

  1. Allow the peptide vial and bacteriostatic water to reach room temperature
  2. Using a sterile syringe, draw the desired volume of bacteriostatic water (typically 2.5 mL for a 5 mg vial)
  3. Inject the water slowly against the vial wall, allowing it to run down gently. Do not spray directly onto the powder
  4. Swirl gently until fully dissolved; never shake, as this can denature the peptide
  5. The solution should be clear and colorless; discard if cloudy or particulate

Dosing Calculation Example:

If reconstituting 5 mg with 2.5 mL bacteriostatic water, the concentration is 2 mg/mL (2000 mcg/mL). For a 100 mcg dose, draw 0.05 mL (5 units on a standard U-100 insulin syringe).

Storage Guidelines:

  • Unreconstituted powder: Stable at room temperature for months; refrigeration extends shelf life to 12 or more months
  • Reconstituted solution: Refrigerate at 2 to 8 degrees C (36 to 46 degrees F); use within 28 days
  • Never freeze reconstituted peptides
  • Protect from light and heat
  • Use bacteriostatic water (containing 0.9% benzyl alcohol) rather than sterile water for multi-dose vials to prevent bacterial contamination

Frequently Asked Questions

Both are hexapeptide GH secretagogues acting on the ghrelin receptor, but GHRP-6 produces significantly stronger appetite stimulation. GHRP-2 is considered slightly more potent for GH release per microgram and causes less hunger, making it the preferred choice when appetite is unwanted.

Yes. GHRP-6 produces the most pronounced appetite stimulation of any GHRP, often described as intense hunger within 15 to 20 minutes of injection. This effect is mediated directly through ghrelin receptor activation in the hypothalamus and is not caused by hypoglycemia.

The commonly cited saturation dose is approximately 1 mcg/kg of body weight, which translates to roughly 100 mcg per injection for most adults. Doses are typically administered two to three times daily on an empty stomach. Exceeding the saturation dose does not proportionally increase GH release but does elevate cortisol and prolactin.

The most common side effect is intense hunger shortly after injection. Other effects include mild water retention, transient flushing or dizziness, and tingling in the extremities. At doses above the saturation threshold, GHRP-6 can elevate cortisol and prolactin levels. These effects are generally dose-dependent and transient.

GHRP-6 is not FDA-approved for human use and cannot be legally sold as a therapeutic or dietary supplement. It is available for purchase as a research chemical in many jurisdictions. It is banned by WADA in all competitive sports. Legal status varies by country, so users should verify local regulations.

GHRP-6 is administered via subcutaneous injection, typically into abdominal fat, the thigh, or the deltoid. It should be injected on an empty stomach, at least 30 minutes before eating or 2 or more hours after a meal, as elevated insulin blunts GH release. The most common protocol is two to three injections daily.

GHRP-6 elevates endogenous growth hormone, which supports protein synthesis, recovery, and lean body composition over time. However, the GH elevations from GHRP-6 are modest compared to exogenous HGH, and meaningful body composition changes typically require consistent use over 8 to 12 weeks alongside proper training and nutrition.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Bowers CY, et al. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537-1545.
  2. Howard AD, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977.
  3. Kojima M, Kangawa K. Ghrelin: structure and function. Physiological Reviews. 2005;85(2):495-522.
  4. Berlanga-Acosta J, et al. Synthetic growth hormone-releasing peptides (GHRPs): a historical appraisal of the evidences supporting their cytoprotective effects. Clin Med Insights Cardiol. 2017;11:1179546817694558.
  5. Leal-Cerro A, et al. Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation. J Clin Endocrinol Metab. 1998;83(4):1186-1189.
  6. Pena-Bello L, et al. Effects of ghrelin, growth hormone-releasing peptide-6, and growth hormone-releasing hormone on growth hormone, adrenocorticotropic hormone, and cortisol release in type 1 diabetes mellitus. Metabolism. 2010;59(11):1536-1542.
  7. Bellone J, et al. Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature. Eur J Endocrinol. 1995;133(4):425-430.
  8. Sosa-Hernandez JL, et al. Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms. Front Pharmacol. 2024;15:1402138.
  9. Berlanga-Acosta J, et al. Growth-hormone-releasing peptide 6 (GHRP6) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction. Clin Sci (Lond). 2007;112(4):241-250.
  10. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.
  11. World Anti-Doping Agency. The Prohibited List.
  12. Fernandez-Perez L, et al. Pharmacokinetic study of growth hormone-releasing peptide 6 (GHRP-6) in nine male healthy volunteers. Eur J Pharm Sci. 2013;48(1-2):40-46.
←Read the full GHRP-6 guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”